x

Posted 11 May, 2023

THERALINK TECHNOLOGIES, INC. appointed new CEO

CEO Change detected for ticker OTC:THER in a 8-K filed on 11 May, 2023.


  On May 5, 2023, Theralink Technologies, Inc. (the "Company") appointed Andrew Kucharchuk, a member of the Board of Directors of the Company, as its Chief Financial Officer, effective May 8, 2023. Mr. Kucharchuk was previously the Chief Executive Officer and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc., the Company's predecessor.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of THERALINK TECHNOLOGIES, INC.
Health Care/Life Sciences • Pharmaceuticals
Theralink Technologies, Inc. is a precision medicine company, which engages in the development of novel cancer immunotherapy products. It offers the reverse phase protein array technology platform that can quantify protein signaling to support oncology clinical treatment decisions and biopharmaceutical drug development. The company was founded on March 18, 2005 and is headquartered in Golden, CO.
Market Cap
$6.15M
View Company Details
THERALINK TECHNOLOGIES, INC. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.


Appointment of Chief Financial Officer


On May 5, 2023, Theralink Technologies, Inc. (the "Company") appointed Andrew Kucharchuk, a member of the Board of Directors of the Company, as its Chief Financial Officer, effective May 8, 2023. Mr. Kucharchuk was previously the Chief Executive Officer and Chief Financial Officer of OncBioMune Pharmaceuticals, Inc., the Company's predecessor. The Company and Mr. Kucharchuk agreed that Mr. Kucharchuk's base salary will be $180,000 per year, and he will be eligible to participate in the benefit plans and programs generally available to the Company's employees. Mr. Kucharchuk will also be entitled to reimbursement of all reasonable business expenses incurred or paid by him in the performance of his duties and responsibilities for the Company, subject to receipt of evidence of such expenses reasonably satisfactory to the Company.


Termination of Chief Financial Officer


On May 5, 2023, the Company terminated the employment of Thomas Chilcott, effective immediately. Mr. Chilcott previously served as the Company's Chief Financial Officer, Treasurer and Secretary.